FIELD: chemistry.
SUBSTANCE: invention relates to the use of a heterocyclic compound of the general formula I for production. In the general formula I R1-R5, R7-R10 – hydrogen, R6 is Cl, or where R1 is CH3, R2-R10 is hydrogen, and R8 is F. 
(I).
EFFECT: drug is intended for prevention and/or treatment of the neurodegenerative disease, which is an early stage of Alzheimer's disease and Alzheimer's type dementia.
1 cl, 13 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF A BENZOPYRAN DERIVATIVE FOR THE TREATMENT OF DEMENTIA OF ALZHEIMER'S TYPE ASSOCIATED WITH CALCIUM DYSREGULATION | 2023 |
|
RU2804398C1 |
| INVENTION OF PROTEIN PI4KIIIA AND RELATED MEMBRANE PROTEIN COMPLEX IN TREATMENT OF ALZHEIMER'S DISEASE | 2016 |
|
RU2724493C2 |
| ANIMAL MODEL OF ZINC-DEPENDENT AMYLOIDOGENESIS IN ALZHEIMER'S DISEASE | 2021 |
|
RU2781331C1 |
| PHARMACEUTICAL COMPOSITION FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASE | 2012 |
|
RU2618412C2 |
| DONECOPRID AS A NEUROPROTECTIVE AGENT IN THE TREATMENT OF NEURODEGERATIVE DISEASES | 2019 |
|
RU2800802C2 |
| 4-(3-((2-ADAMANTYL)AMINO)-3-OXOPROP-1-EN-1-YL)-N-HYDROXYBENZAMIDE - A NEW DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE | 2022 |
|
RU2783995C1 |
| METHOD FOR ASSESSING COMPLEX PROTECTION OF CELLS UNDER NEURO-INFLAMMATORY ON IN VITRO MODELS UNDER EXPOSURE TO PAR1 AGONIST | 2022 |
|
RU2796524C1 |
| PEPTIDE FOR TREATMENT OF ALZHEIMER'S DISEASE | 2017 |
|
RU2678987C2 |
| INTERLEUKIN-10, USING IT AND BASED COMPOSITION FOR TREATING BRAIN NEURODEGENERATIVE PROCESSES | 2012 |
|
RU2538613C2 |
| NEUROTRYPSIN INHIBITORS | 2006 |
|
RU2424228C2 |
